Erlotinib in Treating Patients With Liver Cancer That Cannot be Surgically Removed

Summary

Phase II trial to study the effectiveness of erlotinib in treating patients who have liver cancer that cannot be surgically removed. Erlotinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth

Timeline

Start

2002-08

Primary completion

2006-01

Completion

—

Outcome

Outcome not reported

Stopped: “Administratively complete.”

Drugs

Indications